Want to see HK:2496 full AI Analyst Report?

Wuhan YZY Biopharma Co., Ltd. Class H (2496) Financial Statements

1 Followers

Wuhan YZY Biopharma Co., Ltd. Class H Financial Overview

Wuhan YZY Biopharma Co., Ltd. Class H's market cap is currently HK$639.70M. The company's EPS TTM is HK$-0.2447; its P/E ratio is -11.52; Wuhan YZY Biopharma Co., Ltd. Class H is scheduled to report earnings on August 28, 2026, and the estimated EPS forecast is HK$―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Income Statement
Total Revenue	¥ 65.13M	¥ 107.81M	¥ 11.92M	¥ 2.26M	¥ 12.18M
Gross Profit	¥ 6.17M	¥ 85.07M	¥ 11.92M	¥ 2.26M	¥ 12.18M
Operating Income	¥ -87.93M	¥ -98.00M	¥ -177.37M	¥ -175.58M	¥ -132.23M
EBITDA	¥ -83.65M	¥ -86.95M	¥ -158.39M	¥ -169.23M	¥ -125.20M
Net Income	¥ -82.54M	¥ -97.60M	¥ -190.98M	¥ -188.87M	¥ -148.52M
Balance Sheet
Cash & Short-Term Investments	¥ 100.11M	¥ 126.28M	¥ 196.68M	¥ 200.52M	¥ 83.71M
Total Assets	¥ 175.08M	¥ 267.84M	¥ 301.62M	¥ 265.92M	¥ 163.33M
Total Debt	¥ 127.81M	¥ 127.35M	¥ 90.11M	¥ 67.32M	¥ 28.48M
Net Debt	¥ 27.70M	¥ 1.08M	¥ -106.57M	¥ -67.48M	¥ -39.32M
Total Liabilities	¥ 228.13M	¥ 237.31M	¥ 173.97M	¥ 129.05M	¥ 46.51M
Stockholders' Equity	¥ -53.05M	¥ 30.54M	¥ 127.65M	¥ 155.88M	¥ 143.16M
Cash Flow
Free Cash Flow	¥ -22.46M	¥ -102.22M	¥ -187.95M	¥ -156.40M	¥ -82.10M
Operating Cash Flow	¥ -21.57M	¥ -100.72M	¥ -186.02M	¥ -155.16M	¥ -80.55M
Investing Cash Flow	¥ -130.00K	¥ -4.67M	¥ 54.81M	¥ 5.10M	¥ -16.27M
Financing Cash Flow	¥ -4.68M	¥ 33.02M	¥ 176.29M	¥ 241.33M	¥ 81.03M

Currency in CNY

Wuhan YZY Biopharma Co., Ltd. Class H Earnings and Revenue History

Income Statement >

Wuhan YZY Biopharma Co., Ltd. Class H Debt to Assets

Balance Sheet >

Wuhan YZY Biopharma Co., Ltd. Class H Cash Flow

Cash Flow >

Wuhan YZY Biopharma Co., Ltd. Class H Forecast EPS vs Actual EPS

Earnings >